Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06473103 · ClinicalTrials.gov registry record · NA
Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy
A NA study of Basal Cell Carcinoma, sponsored by University of Rochester.
- Recruiting
- Registry status
- NA
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT06473103: Recruiting NA study of Basal Cell Carcinoma, sponsored by University of Rochester.
NCT06473103 is a NA study of Basal Cell Carcinoma that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 52 participants, below the 102-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06473103, a NA study of Basal Cell Carcinoma, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to compare the use of two photon fluorescence microscopy for detecting residual basal cell carcinoma during standard local excision.
Primary Outcome
The distance from the furthest extent of the tumor to the nearest surgical margin will be measured on both TPFM and conventional paraffin histology and the numerical difference calculated.
Conditions Studied
Interventions
- DEVICE Two photon fluorescence microscopy imaging
Study Locations (1)
New York
- Rochester Dermatologic Surgery - Victor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2026-04 |
| Phase | NA |
What NCT06473103 shows while recruiting
NCT06473103 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 102-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Basal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Two photon fluorescence microscopy imaging is the first listed.
NCT06473103 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06473103 about?
NCT06473103 is a clinical study titled "Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy". The goal of this clinical trial is to compare the use of two photon fluorescence microscopy for detecting residual basal cell carcinoma during standard local excision.
What is the current status of trial NCT06473103?
This trial is currently recruiting. It is a NA study. The enrollment target is 52 participants. The study started on 2024-10-29. Estimated completion is 2026-04.
What conditions does trial NCT06473103 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma.
What interventions are being tested in trial NCT06473103?
The interventions under investigation include: Two photon fluorescence microscopy imaging (DEVICE).
Who is sponsoring clinical trial NCT06473103?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06473103 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06473103's enrollment target sits among peer trials
52 11th of 24 higher than 14 of 24 other Basal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Basal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma
RECRUITING · NA
-
Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas
RECRUITING · NA
-
Safety and Efficacy of Oral Midazolam for Perioperative Anxiety Relief of Patients Undergoing Mohs Micrographic Surgery
COMPLETED · NA
-
Video-Based Treatment Options for Basal Cell Carcinoma
COMPLETED · NA
-
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI